{{Rsnum
|rsid=362307
|Gene=HTT
|Chromosome=4
|position=3240118
|Orientation=plus
|GMAF=0.03581
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=HTT
}}{{PharmGKB
|RSID=rs362307
|Name_s=
|Gene_s=C4orf44, HTT
|Feature=
|Evidence=PubMed ID:19249009
|Annotation=This SNP is part of a haplogroup found to be associated with CAG repeat number expansion in Huntington disease (36 or more CAG repeats) in Europeans and also with intermediate expansion(27-35 repeats) in unaffected individuals(Europeans). This SNP itself was significantly associated(p < 0.0023) with the expansion.
|Drugs=
|Drug Classes=
|Diseases=Huntington Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA164918152
}}

{{PMID|19361997|OA=1
}} Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs362307
|overall_frequency_n=3
|overall_frequency_d=128
|overall_frequency=0.0234375
|n_genomes=3
|n_genomes_annotated=0
|n_haplomes=3
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}